PH12012501494A1 - Treatment of cardiac conditions - Google Patents

Treatment of cardiac conditions

Info

Publication number
PH12012501494A1
PH12012501494A1 PH1/2012/501494A PH12012501494A PH12012501494A1 PH 12012501494 A1 PH12012501494 A1 PH 12012501494A1 PH 12012501494 A PH12012501494 A PH 12012501494A PH 12012501494 A1 PH12012501494 A1 PH 12012501494A1
Authority
PH
Philippines
Prior art keywords
treatment
cardiac conditions
glucagon
dobutamine
norepinephrine
Prior art date
Application number
PH1/2012/501494A
Other languages
English (en)
Inventor
Lene Axelsen
Keld Fosgerau
Rie Schultz Hansen
Anne Louise Kjoelbye
Bjarne Due Larsen
Eddi Meier
Henrik Duelund Pedersen
Jã¸Rgen Sã¸Berg Petersen
Ditte Riber
Marie Skovgaard
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12012501494(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of PH12012501494A1 publication Critical patent/PH12012501494A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PH1/2012/501494A 2010-01-20 2011-01-20 Treatment of cardiac conditions PH12012501494A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29665710P 2010-01-20 2010-01-20
PCT/DK2011/050018 WO2011088837A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Publications (1)

Publication Number Publication Date
PH12012501494A1 true PH12012501494A1 (en) 2012-10-22

Family

ID=43928934

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2012/501494A PH12012501494A1 (en) 2010-01-20 2011-01-20 Treatment of cardiac conditions

Country Status (15)

Country Link
US (1) US20130157953A1 (https=)
EP (1) EP2525809B1 (https=)
JP (2) JP2013517307A (https=)
KR (1) KR20120128129A (https=)
CN (1) CN102892425A (https=)
AU (1) AU2011206979B2 (https=)
BR (1) BR112012018104A2 (https=)
CA (1) CA2786934A1 (https=)
CL (1) CL2012002037A1 (https=)
EA (1) EA026384B1 (https=)
IL (1) IL220876A0 (https=)
MX (1) MX342409B (https=)
NZ (1) NZ601167A (https=)
PH (1) PH12012501494A1 (https=)
WO (1) WO2011088837A1 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2477880T3 (es) 2008-12-15 2014-07-18 Zealand Pharma A/S Análogos del glucagón
CN102282167B (zh) 2008-12-15 2014-08-13 西兰制药公司 胰高血糖素类似物
EP2370462B1 (en) 2008-12-15 2014-07-16 Zealand Pharma A/S Glucagon analogues
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
AU2010272944B2 (en) 2009-07-13 2015-11-19 Zealand Pharma A/S Acylated glucagon analogues
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
US9169310B2 (en) * 2010-06-24 2015-10-27 Zealand Pharma A/S Glucagon analogues
TW201326194A (zh) 2011-11-03 2013-07-01 Zealand Pharma As Ｇｌｐ－１胃泌素受體促效劑肽結合物
IN2014CN04401A (https=) * 2011-12-23 2015-09-04 Zealand Pharma As
IN2014MN02304A (https=) 2012-05-03 2015-08-07 Zealand Pharma As
IN2015DN00544A (https=) 2012-07-23 2015-06-26 Zealand Pharma As
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) * 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
MX360816B (es) * 2012-11-20 2018-11-15 Mederis Diabetes Llc Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.
JP2016503046A (ja) * 2012-12-19 2016-02-01 ノヴォ ノルディスク アー／エス コレステロール流出活性を有する新規ｇｌｐ−１受容体アゴニスト
AU2013366692B2 (en) 2012-12-21 2017-11-23 Sanofi Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
PL3057984T3 (pl) 2013-10-17 2018-12-31 Zealand Pharma A/S Acylowane analogi glukagonu
WO2015067715A2 (en) * 2013-11-06 2015-05-14 Zealand Pharma A/S Gip-glp-1 dual agonist compounds and methods
CN105829339B (zh) 2013-11-06 2021-03-12 西兰制药公司 胰高血糖素-glp-1-gip三重激动剂化合物
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
AR098616A1 (es) 2013-12-18 2016-06-01 Lilly Co Eli Péptido para el tratamiento de hipoglicemia severa
CN103724424B (zh) * 2013-12-27 2015-05-27 浙江省农业科学院 一种mPEG-SPA-pGLP-2复合物及其制备方法和应用
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN107108713A (zh) 2014-10-10 2017-08-29 诺和诺德股份有限公司 稳定的基于glp‑1的glp‑1/胰高血糖素受体共激动剂
KR102620911B1 (ko) 2014-10-29 2024-01-05 질랜드 파마 에이/에스 Gip 효능제 화합물 및 방법
PE20171154A1 (es) * 2014-12-30 2017-08-16 Hanmi Pharm Ind Co Ltd Derivados de glucagon con estabilidad mejorada
KR102418477B1 (ko) * 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
WO2016168388A2 (en) * 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
DK3283507T3 (da) 2015-04-16 2020-01-02 Zealand Pharma As Acyleret glucagonanalog
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
EP4523705A3 (en) 2015-06-30 2025-06-11 Hanmi Pharm. Co., Ltd. Glucagon derivative and a composition comprising a long acting conjugate of the same
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
SG11201805586SA (en) 2015-12-31 2018-07-30 Hanmi Pharmaceutical Co Ltd Triple glucagon/glp-1/gip receptor agonist
US11179444B2 (en) 2016-06-09 2021-11-23 Amidebio, Llc Glucagon analogs and methods of use thereof
EP3479841A4 (en) 2016-06-29 2020-03-04 Hanmi Pharm. Co., Ltd. GLUCAGON DERIVATIVE, CONJUGATE THEREOF, COMPOSITION THEREOF AND THERAPEUTIC USE THEREOF
EP3551651B1 (en) 2016-12-09 2024-03-06 Zealand Pharma A/S Acylated glp-1/glp-2 dual agonists
CN109836503B (zh) * 2017-11-24 2022-09-16 浙江道尔生物科技有限公司 一种治疗代谢疾病的多重活性蛋白
CN109836488B (zh) * 2017-11-24 2022-08-23 浙江道尔生物科技有限公司 一种治疗代谢疾病的胰高血糖素类似物
AR113486A1 (es) * 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
EP4506017A3 (en) 2018-01-03 2025-05-14 Mederis Diabetes, LLC Improved peptide pharmaceuticals for treatment of nash and other disorders
WO2021083306A1 (zh) * 2019-10-31 2021-05-06 东莞市东阳光生物药研发有限公司 Glp-1/gcg双受体激动剂多肽
EP3842060A1 (en) * 2019-12-23 2021-06-30 Merck Sharp & Dohme Corp. Stapled lactam co-agonists of the glucagon and glp-1 receptors
KR102886870B1 (ko) * 2020-05-09 2025-11-18 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 이중 수용체 아고니즘 작용을 갖는 폴리펩티드 유도체 및 그 용도
CN117202924A (zh) 2020-12-07 2023-12-08 斯皮特弗尔制药有限责任公司 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1054594B1 (en) * 1998-02-13 2007-07-04 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and glp-1
US6703359B1 (en) * 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
NZ506839A (en) 1998-03-09 2003-05-30 Zealand Pharma As Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
NZ519752A (en) * 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
US7192922B2 (en) * 2002-11-19 2007-03-20 Allegheny-Singer Research Institute Method of treating left ventricular dysfunction
CA2638800A1 (en) 2006-02-22 2007-09-07 Merck & Co., Inc. Oxyntomodulin derivatives
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
CA2677932A1 (en) * 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2158214B1 (en) * 2007-06-15 2011-08-17 Zealand Pharma A/S Glucagon analogues
US8450270B2 (en) 2008-06-17 2013-05-28 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability in physiological pH buffers
AR072160A1 (es) * 2008-06-17 2010-08-11 Univ Indiana Res & Tech Corp Co-agonistas del receptor de glucagon/glp-1
US20100240883A1 (en) * 2009-03-18 2010-09-23 Nian Wu Lipid-drug conjugates for drug delivery
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物

Also Published As

Publication number Publication date
EP2525809B1 (en) 2016-08-03
JP6200025B2 (ja) 2017-09-20
CL2012002037A1 (es) 2012-09-07
JP2016138127A (ja) 2016-08-04
MX2012008440A (es) 2012-08-15
KR20120128129A (ko) 2012-11-26
WO2011088837A1 (en) 2011-07-28
BR112012018104A2 (pt) 2017-10-17
IL220876A0 (en) 2012-09-24
JP2013517307A (ja) 2013-05-16
MX342409B (es) 2016-09-28
NZ601167A (en) 2014-12-24
CN102892425A (zh) 2013-01-23
EA026384B1 (ru) 2017-04-28
EP2525809A1 (en) 2012-11-28
AU2011206979A1 (en) 2012-08-02
AU2011206979B2 (en) 2015-09-10
US20130157953A1 (en) 2013-06-20
CA2786934A1 (en) 2011-07-28
EA201290540A1 (ru) 2013-03-29

Similar Documents

Publication Publication Date Title
PH12012501494A1 (en) Treatment of cardiac conditions
MX2016005556A (es) Compuestos agonistas duales de gip-glp-1 y procedimientos.
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
MX2015008114A (es) Derivados de exendina-4.
WO2012104007A3 (de) 7-azaindolderivate
GB201116010D0 (en) Use of alginate oligomers to enhance the effects of antifungal agents
PH12014502286A1 (en) Improving resistance to skeletal muscle fatigue
MY188227A (en) Settable compositions comprising wollastonite and pumice and methods of use
MX342947B (es) Tratamiento de diabetes tipo 2.
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
PT2531189E (pt) Composição de combinação, que compreende como ingrediente activo l-carnitina ou propionil l-carnitina, para a prevenção ou o tratamento da insuficiência venosa crónica
ZA201401487B (en) Left ventricular diastolic function improving agent
PT2770979E (pt) Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone
BR112012002353A2 (pt) uso de inibidores nkg2d para tratamento de doenças cardiovasculares e metabólicas, tal como diabetes do tipo 2
MX362111B (es) Un metodo para mejorar la funcion hepatica.
EA201491455A1 (ru) ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
LT2460509T (lt) Kompozicija, skirta karpų gydymui
LT2702033T (lt) 3-karboksi-n-etil-n,n-dimetilpropan-1-amino druskos panaudojimas kardiovaskuliarinių ligų gydyme
WO2011146560A3 (en) Use of jasmonates for treating heart failure and related cardiac disorders
EA201492173A1 (ru) Дронедарон для применения при лейшманиозе, в составах и комбинациях для применения при лейшманиозе
AP2014007596A0 (en) Composition to be applied to the skin, and use thereof
UA60249U (ru) Способ лечения острого инфаркта миокарда
UA96059C2 (ru) Применение липина как средства фригопротекторного действия
ZA201206518B (en) Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency